Low Evidence
Research Overview
IGF-1 LR3 Research for Muscle Growth
An evidence-based overview of research examining IGF-1 LR3 in the context of muscle growth. This page synthesizes findings from peer-reviewed literature.
Research Summary
IGF-1 LR3's extended half-life and reduced IGFBP binding make it a potent activator of the PI3K/Akt/mTOR pathway for muscle protein synthesis. Animal studies show clear hypertrophic effects. Human data is limited to extrapolation from native IGF-1 studies.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. IGF-1 LR3 has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.